Abbonarsi

Can pretreatment serum calcium level predict the efficacy of methotrexate in the treatment of severe plaque psoriasis? - 12/11/15

Doi : 10.1016/j.jaad.2015.08.036 
Zhifang Zhai, MD, PhD a, Ling Chen, MD b, Huan Yang, MD c, Jun Yan, PhD d, Chunyou Wang, MD a, Jinxin Yang, BA a, Wenying Liu, MS a, Zhu Shen, MD, PhD a,
a Department of Dermatology, Southwest Hospital, Third Military Medical University, Chongqing, China 
b Department of Dermatology, Daping Hospital, Third Military Medical University, Chongqing, China 
c Institute of Toxicology, Third Military Medical University, Chongqing, China 
d State Key Laboratory of Trauma, Burns and Combined Injury, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China 

Correspondence to: Zhu Shen, MD, PhD, Dermatology Department, Southwest Hospital, Third Military Medical University, No 30 Gaotanyan Main Street, Shapingba District, Chongqing, 400038 China.

Abstract

Background

The efficacy of methotrexate (MTX) varies in the treatment of psoriasis.

Objective

We sought to identify an indicator from routine pretreatment tests to predict MTX efficacy in the treatment of psoriasis.

Methods

In a retrospective analysis of 77 psoriatic patients, the correlation between MTX efficacy and pretreatment routine test results was analyzed with Spearman correlation. The potential risks were further evaluated with a linear regression model. Receiver operating characteristic analysis was performed to examine the effectiveness of serum total calcium (tCa) to predict the effect of MTX on psoriasis. The highest Youden index was used to determine the cutoff point, with which the positive and negative predictive values were calculated. Synergistic effects of MTX and calcium on keratinocyte growth and psoriasis-like mouse model were also investigated.

Results

The pretreatment tCa level exhibited the closest association with MTX efficacy. The relative psoriasis improvement with tCa was 61.07% (95% confidence interval, 42.85-79.29; P < .001) and better improvements were observed in patients with higher tCa (r = 0.588; P < .002). MTX inhibited keratinocyte growth, which was enhanced synergistically by calcium. In a psoriasis-like mouse model, MTX strongly inhibited epidermis proliferation in the high-calcium group.

Limitations

One limitation of our study is the relatively small sample size.

Conclusion

Pretreatment tCa level has the highest correlation with MTX efficacy, which might be useful in predicting beneficial treatment results in psoriasis. Larger studies are required to confirm our findings.

Il testo completo di questo articolo è disponibile in PDF.

Key words : calcium, keratinocyte, methotrexate, predictor, psoriasis, treatment efficacy


Mappa


 Supported in part by National Natural Science Foundation of China (no. 81373237) and Clinical Innovative Project of Third Military Medical University (SWH2012LC13).
 Conflicts of interest: None declared.


© 2015  American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 73 - N° 6

P. 991 - dicembre 2015 Ritorno al numero
Articolo precedente Articolo precedente
  • Facial lesions in frontal fibrosing alopecia (FFA): Clinicopathological features in a series of 12 cases
  • Arantxa López-Pestaña, Anna Tuneu, Carmen Lobo, Nerea Ormaechea, José Zubizarreta, Susana Vildosola, Elena Del Alcazar
| Articolo seguente Articolo seguente
  • Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS)
  • Schapoor Hessam, Michael Sand, Thilo Gambichler, Falk G. Bechara

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.